Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic: current and future perspective | Zendy

Matti Aapro | Zendy; Li Zhang | Zendy; Sriram Yennu | Zendy; Thomas W. LeBlanc | Zendy; Lee S. Schwartzberg | Zendy

Open Access

Preventing chemotherapy-induced nausea and vomiting with netupitant/palonosetron, the first fixed combination antiemetic: current and future perspective

Author(s) -

Matti Aapro,

Li Zhang,

Sriram Yennu,

Thomas W. LeBlanc,

Lee S. Schwartzberg

Publication year - 2019

Publication title -

future oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.857

H-Index - 72

eISSN - 1744-8301

pISSN - 1479-6694

DOI - 10.2217/fon-2018-0872

Subject(s) - palonosetron , chemotherapy induced nausea and vomiting , antiemetic , medicine , nausea , vomiting , guideline , intensive care medicine , anesthesia , pathology

Chemotherapy-induced nausea and vomiting (CINV) can be prevented in most patients receiving appropriate antiemetic treatment. However, inadequate uptake of current antiemetic guideline recommendations by physicians, and poor treatment adherence by patients, lead to suboptimal CINV control. There is an unmet need to optimize guideline-consistent use of antiemetics to improve CINV management and prevention. Herein, we provide an overview of CINV, then discuss oral and intravenous NEPA, the first fixed combination antiemetic, composed of netupitant/fosnetupitant and palonosetron. We describe the main pharmacologic and pharmacokinetic characteristics of NEPA, and review the clinical evidence supporting its use in the prevention of CINV.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research